NAFLD的发病机制与新型治疗药物研发  

Pathogenesis of Nonalcoholic Fatty Liver Disease and Development of New Therapeutic Drugs

作　　者：于文雪 孙禹欣 金莉莉[1] 王秋雨[1] YU Wenxue;SUN Yuxin;JIN Lili;WANG Qiuyu(Life Science School,Liaoning University,Shenyang 110036,China)

机构地区：[1]辽宁大学生命科学院,沈阳110036

出　　处：《中国细胞生物学学报》2020年第3期499-506,共8页Chinese Journal of Cell Biology

基　　金：辽宁省科学事业公益基金研究项目(批准号:GY-2017-0022);国家自然科学基金(批准号:31071916)资助的课题。

摘　　要：NAFLD(nonalcoholic fatty liver disease)是一种常见的慢性肝脏疾病。随着病情的发展,NAFLD还会引发2型糖尿病、心血管疾病等。目前较为常见的治疗药物包括调脂类药物、过氧化物酶体增长因子活化受体激动剂、保肝抗炎类药物等,尚缺乏针对NAFLD的特效药物。近年来发现,NAFLD的发病机制与胰岛素抵抗密切相关,促胰岛素分泌型抗菌肽具有缓解胰岛素抵抗和治疗NAFLD的功效。该文综述了NAFLD发病机制和治疗药物的研究进展,并结合作者实验室相关的研究工作,分析了促胰岛素分泌型抗菌肽治疗NAFLD的优势。NAFLD (nonalcoholic fatty liver disease) is a common chronic fatty liver disease.With the development of the disease,it can also cause type 2 diabetes,cardiovascular disease and so on.At present,the common treatments include lipid-lowering drugs,peroxisome growth factor activating receptor agonists,liver-protecting anti-inflammatory drugs,etc.But there is a lack of specific drugs for NAFLD.It is found that the pathogenesis of NAFLD is closely related to insulin resistance by researches.Antibacterial peptides promoting insulin can alleviate insulin resistance and treat NAFLD.This article reviews the pathogenesis of NAFLD and researches of therapeutic drugs.Combined with the researches of the author’s laboratory,the advantages of insulin-promoting antibacterial peptides in the treatment of NAFLD are analzed.

关 键 词：NAFLD 胰岛素抵抗 AMPK信号通路 抗菌肽 

分 类 号：R575.5[医药卫生—消化系统]